Medicine
Semaglutide news, research, studies, and rapid health briefings. Visit Viral Vitalism for plain-language context, evidence boundaries, and related signals.
GLP-1 medications are being studied for effects that may extend beyond weight loss, including cardiometabolic outcomes and behavior-related pathways.
VV Signal Score
76
Promising signal
GLP-1 medications may do more than reduce appetite for food. Early clinical trials, real-world data, and preclinical research suggest they may also affect craving, reward, alcohol intake, and substance-use patterns - but the science is still developing.
VV Signal Score
57
Early or context-dependent
News cycle
The weight-loss drug boom created a shadow market of compounded GLP-1s, fake labels, telehealth claims, dosing confusion, and patients who may not know what they are actually getting.
Why now
Regulatory warnings and investigations are converging on the same problem: patients cannot always tell what product they are receiving.
Research map
Research records connected to this topic through topic tags, source records, and timeline events.
Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis
Clinical trial from 2025 in PubMed, translated into key findings, limitations, and consumer relevance.
Why this appears: Shown as discovery context only because no accepted page-level relationship metadata was supplied.
PubMed / 2025->
Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes
Clinical trial from 2024 in New England Journal of Medicine, translated into key findings, limitations, and consumer relevance.
Why this appears: Shown as discovery context only because no accepted page-level relationship metadata was supplied.
New England Journal of Medicine / 2024->
Semaglutide and cardiovascular outcomes in obesity without diabetes
Cardiovascular outcomes trial from 2023 in New England Journal of Medicine, translated into key findings, limitations, and consumer relevance.
Why this appears: Shown as discovery context only because no accepted page-level relationship metadata was supplied.
New England Journal of Medicine / 2023->
Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity
Randomized trial from 2026 in The Lancet, translated into key findings, limitations, and consumer relevance.
Why this appears: Shown as discovery context only because no accepted page-level relationship metadata was supplied.
The Lancet / 2026->
Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population
Observational study from 2024 in Nature Communications, translated into key findings, limitations, and consumer relevance.
Why this appears: Shown as discovery context only because no accepted page-level relationship metadata was supplied.
Nature Communications / 2024->
Once-Weekly Semaglutide in Adults With Alcohol Use Disorder
Randomized trial from 2025 in JAMA Psychiatry, translated into key findings, limitations, and consumer relevance.
Why this appears: Shown as discovery context only because no accepted page-level relationship metadata was supplied.
JAMA Psychiatry / 2025->
Vital Signals
Get the weekly health signal without the wellness fog.
A clean weekly brief covering longevity science, fitness, nutrition, medicine, health culture, and the claims worth questioning.
No spam. No selling your information. Unsubscribe anytime.
By subscribing, you agree to receive email from Viral Vitalism. Unsubscribe anytime. See our Privacy Policy.
